SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients.
Adult
Antibodies, Monoclonal, Humanized
/ administration & dosage
COVID-19
/ complications
Female
Humans
Interferons
/ genetics
Male
Mutation
Polyendocrinopathies, Autoimmune
/ complications
SARS-CoV-2
/ genetics
Spike Glycoprotein, Coronavirus
/ genetics
Transcription Factors
/ genetics
COVID-19 Drug Treatment
AIRE Protein
AIRE
APECED
APS-1
COVID-19
bamlanivimab-etesevimab
pneumonitis
type-1 IFN autoantibodies
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
06
2021
accepted:
03
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
18
9
2021
Statut:
epublish
Résumé
Patients with the monogenic immune dysregulatory syndrome autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), which is caused by loss-of-function mutations in the autoimmune regulator (
Identifiants
pubmed: 34504497
doi: 10.3389/fimmu.2021.720205
pmc: PMC8421855
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Spike Glycoprotein, Coronavirus
0
Transcription Factors
0
spike protein, SARS-CoV-2
0
bamlanivimab
45I6OFJ8QH
Interferons
9008-11-1
etesevimab
N7Q9NLF11I
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
720205Informations de copyright
Copyright © 2021 Ferré, Schmitt, Ochoa, Rosen, Shaw, Burbelo, Stoddard, Rampertaap, DiMaggio, Bergerson, Rosenzweig, Notarangelo, Holland and Lionakis.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
JCI Insight. 2016 Aug 18;1(13):
pubmed: 27588307
Immunol Cell Biol. 2021 Jul 26;:
pubmed: 34309902
J Endocrinol Invest. 2020 Aug;43(8):1175-1177
pubmed: 32519200
Immunol Rev. 2019 Jan;287(1):103-120
pubmed: 30565240
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
J Clin Immunol. 2021 Jul;41(5):931-933
pubmed: 33763778
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Sci Transl Med. 2019 Jun 5;11(495):
pubmed: 31167928
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
Curr Opin Immunol. 2017 Dec;49:71-78
pubmed: 29065385
J Exp Med. 2021 Jul 5;218(7):
pubmed: 33890986
J Allergy Clin Immunol. 2021 Jul;148(1):96-98
pubmed: 33892926
Front Immunol. 2021 Jan 27;11:609253
pubmed: 33584685
J Clin Invest. 2021 Jul 15;131(14):
pubmed: 34061776
N Engl J Med. 2021 Jul 14;:
pubmed: 34260849
PLoS Med. 2006 Jul;3(7):e289
pubmed: 16784312
J Infect Dis. 2020 Jun 29;222(2):206-213
pubmed: 32427334
Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
Annu Rev Immunol. 2009;27:287-312
pubmed: 19302042
J Clin Immunol. 2021 Apr;41(3):536-544
pubmed: 33616813
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Nat Rev Immunol. 2016 Apr;16(4):247-58
pubmed: 26972725
J Clin Immunol. 2021 Jul;41(5):914-922
pubmed: 33851338
J Allergy Clin Immunol. 2021 Feb;147(2):520-531
pubmed: 32980424
JAMA. 2020 Aug 18;324(7):663-673
pubmed: 32706371
Med (N Y). 2020 Dec 18;1(1):14-20
pubmed: 33363283
Sci Transl Med. 2021 Aug 24;:
pubmed: 34429372